Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients

• Status: Unknown status
• Trial end date: 2019-02-27
• Target enrollment: 0
• Participant gender: All

Summary

Investigators hypothesize that administration of ketamine for pain relief in sickle cell patients with vaso-occlusive crisis early on will lead to a more rapid improvement in pain score and less narcotic requirement.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dammam University
• Treatments: Ketamine; Morphine

Criteria

Inclusion Criteria:

• Known diagnosis of SCD based on sickle cell tests and hemoglobin electrophoresis.

• Age 18 to 60 years

• Acute onset of painful crises, defined as having an onset within 7 days

Exclusion Criteria:

• Pregnancy

• Breast-feeding

• Altered mental status

• Body mass index greater than 40 kg/m2

• Patients with significant neurological disease

• Seizures

• Acute head injury

• Acute eye injury

• Patients with high intra-cranial tension

• Patients with known psychiatric disorders

• Patients with significant cardiac diseases

• Arrhythmias

• Patients with significant pulmonary diseases rather than acute chest syndrome

• Patients with significant renal disease (BUN/creatinine ratio < 25)

• Patients with significant hepatic disease (Child Pugh class B or C)

• Patients with significant endocrine disease

• Known allergy to phencyclidine derivatives

• Known allergy to ketamine

• Known allergy to morphine

• Sepsis

• Septic shock

• Patients required circulatory support

• Patients required ventilatory supports

• Alcohol abuse

• Drug abuse

• Patients with chronic pain status unrelated to SCD

• Patients receiving anti-convulsant medications

• Patients receiving anti-psychiatric medications.

• Patients with communication barriers.